Zai Lab 9688.HK HK$15.00 close 25 Feb 2026: earnings preview and key outlook
The 9688.HK stock closed at HK$15.00 on 25 Feb 2026 as investors position ahead of Zai Lab’s earnings due 26 Feb 2026. Trading volume reached 12,795,400.00 shares, a 1.29x relative volume versus the average. Expect the report to focus on FY2024 revenue growth, progress on oncology programs, and near-term cash flow signals
Earnings snapshot and market reaction
Zai Lab Limited (9688.HK) ended the session at HK$15.00, down -2.02% from the previous close. Volume was 12,795,400.00 versus average volume 9,885,093.00, signalling heightened trader interest.
Shares traded between HK$14.84 and HK$15.39 today. The stock sits well below its 52-week high of HK$35.50 and above the 52-week low of HK$12.31
What to watch in the 26 Feb 2026 earnings report
Investors will watch revenue growth and margins after FY2024 revenue rose 49.59% year-on-year. Management commentary on product sales for Zejula, NUZYRA, and Qinlock will matter to near-term cash flow.
We will also watch R&D spend and pipeline milestones, including clinical readouts for Odronextamab and Repotrectinib, which can change forward guidance and sentiment
9688.HK stock valuation and key financial ratios
Zai Lab trades at PE -10.07 with EPS -1.49 and price-to-sales 4.87. Market capitalisation is HK$16,810,422,300.00, with shares outstanding 1,120,694,820.00.
Liquidity looks reasonable: current ratio 2.87 and cash per share HK$0.65. Free cash flow per share is negative at -0.19, so operating cash trends in the report will be pivotal
Meyka AI grade and model forecast for 9688.HK stock
Meyka AI rates 9688.HK with a score out of 100: 70.97 | Grade B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Meyka AI’s forecast model projects a 12-month price of HK$19.97, versus the current HK$15.00, implying an upside of 33.13%. Forecasts are model-based projections and not guarantees. Refer to our live page for updates: Meyka stock page
Technicals, trend signals and trading levels
Short-term momentum is neutral-positive: RSI 55.87, MACD histogram 0.18, and Stochastic %K 84.54. The 50-day average price is HK$14.23 and the 200-day average is HK$21.94.
Near-term support sits at the day’s low HK$14.84 and at the 50-day average. Immediate resistance is the day high HK$15.39 and the Bollinger upper band at HK$15.87
Sector context, catalysts and risks
Zai Lab operates in Healthcare Biotechnology, where the Hong Kong sector shows 1Y +37.87% and YTD +2.70%. Biotech momentum can lift names on positive trial updates.
Key risks include trial setbacks, regulatory reviews in China, and funding dilution if cash flow weakens. Upcoming data readouts and the earnings call will likely drive headline moves
Final Thoughts
Zai Lab (9688.HK) enters earnings with the stock at HK$15.00 and heightened volume ahead of the 26 Feb 2026 release. Financials show strong revenue growth, with FY2024 up 49.59%, but persistent negative EPS -1.49 and negative free cash flow per share -0.19 underline execution risk. Meyka AI’s model projects HK$19.97 over 12 months, implying 33.13% upside from today. Conservative downside remains near the 52-week low HK$12.31 (-17.93%). Traders should watch guidance, R&D cadence, and cash runway on the call. Our analysis frames this as an earnings-driven trade with binary clinical catalysts and meaningful volatility. Meyka AI provides this as AI-powered market analysis and not investment advice. Forecasts are model-based projections and not guarantees
FAQs
When will Zai Lab report earnings and how does it affect 9688.HK stock?
Zai Lab reports on 26 Feb 2026. Expect trading volatility in 9688.HK stock as investors react to revenue, R&D spend, and guidance. Clinical updates could move the stock significantly
What is Meyka AI’s 12-month forecast for 9688.HK stock?
Meyka AI’s model projects HK$19.97 over 12 months, implying 33.13% upside from the current HK$15.00. Forecasts are model-based projections and not guarantees
What are the main valuation risks for 9688.HK stock?
Valuation risks include negative EPS -1.49, negative free cash flow per share -0.19, and trial or regulatory setbacks. Dilution remains a risk if management raises capital
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.